Prescription medication · Long-Acting Muscarinic Antagonist (LAMA)
glycopyrrolate
Also sold as Seebri, Lonhala. This medicine can help reduce saliva and other secretions before surgery.
Data updated 2026-05-15
- 5,225
- FDA reportsLightly reported
- 2
- InteractionsFew interactions
- 1
- Recall record
What the data shows
glycopyrrolate (Seebri) is a prescription Long-Acting Muscarinic Antagonist (LAMA), reported less often than most tracked drugs (5,225 FDA reports), with 2 documented drug interactions.
Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.
glycopyrrolate (Seebri) is a prescription Long-Acting Muscarinic Antagonist (LAMA). This medicine can help reduce saliva and other secretions before surgery.
Glycopyrrolate injection reduces body secretions before and during surgery. It can also help manage peptic ulcers in adults when quick action is needed.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Generic Price
$1.40/unit
Generic Available
Yes (38 manufacturers)
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
This medicine can help reduce saliva and other secretions before surgery.
Common side effects
Dry mouth, Trouble urinating, Blurred vision
Key warnings
This medicine contains benzyl alcohol, which can be harmful to newborns.
The sections below are summarized in plain English from glycopyrrolate's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Glycopyrrolate blocks the action of a chemical called acetylcholine. This chemical can cause increased saliva, stomach acid, and other body fluids. By blocking acetylcholine, glycopyrrolate reduces these secretions.
Side Effects (from patient reports)
Based on 5,225 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for glycopyrrolate, by number of reports
- Dyspnoea
Dyspnoea
1,000 reports
- Asthma
Asthma
793 reports
- Wheezing
Wheezing
674 reports
- Cough
Cough
626 reports
- Pneumonia
Pneumonia
538 reports
- Fatigue 352
Fatigue
352 reports
- Malaise 345
Malaise
345 reports
- Productive Cough 330
Productive Cough
330 reports
- Chest Discomfort 327
Chest Discomfort
327 reports
- Chronic Obstructive Pulmonary Disease 326
Chronic Obstructive Pulmonary Disease
326 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for glycopyrrolate each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where glycopyrrolate sits
glycopyrrolate has more FDA adverse-event reports than 25% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is glycopyrrolate; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 5,225 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2001–2025.
Total Reports
5,225
Reports Mentioning Death
630
12.1% of reports — not proof of cause
Hospitalization Reports
2,218
Top Indication
Product Used For Unknown Indication
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | DYSPNOEA | 1,000 |
| 2 | ASTHMA | 793 |
| 3 | WHEEZING | 674 |
| 4 | COUGH | 626 |
| 5 | PNEUMONIA | 538 |
| 7 | FATIGUE | 352 |
| 9 | MALAISE | 345 |
| 10 | PRODUCTIVE COUGH | 330 |
| 11 | CHEST DISCOMFORT | 327 |
| 12 | CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 326 |
| 13 | CONDITION AGGRAVATED | 311 |
| 14 | NAUSEA | 311 |
| 15 | PYREXIA | 304 |
| 16 | WEIGHT DECREASED | 301 |
| 17 | THERAPEUTIC PRODUCT EFFECT INCOMPLETE | 282 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
This medicine contains benzyl alcohol, which can be harmful to newborns. If you have glaucoma, trouble urinating, or a blockage in your stomach or intestines, you should not take this medicine for peptic ulcer treatment.
Known Drug Interactions
Concomitant administration of glycopyrrolate injection and potassium chloride in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time.
Mechanism: Glycopyrrolate slows down your digestion, which can cause potassium tablets to sit in your stomach or intestines too long and cause sores.
No significant adverse interactions with commonly used premedications or drugs used during anesthesia and surgery (including atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, d-tubocurarine, succinylcholine and other nondepolarizing muscle relaxants) or topical local anesthetics (including lidocaine, dyclonine HCl and Cetacaine) have been observed in adults or pediatric patients.
Mechanism: These drugs do not have any known harmful interactions when used together during surgery or anesthesia.
This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.
Common Questions
What should I tell my doctor before taking glycopyrrolate?
Can I take glycopyrrolate with other medicines?
What are the signs of an allergic reaction?
Can glycopyrrolate cause mental confusion?
What should I do if I experience severe side effects?
Is glycopyrrolate safe for children?
How is glycopyrrolate given?
Can glycopyrrolate affect my vision?
Can glycopyrrolate cause constipation?
Who makes this medicine?
What are the common side effects of glycopyrrolate?
Does glycopyrrolate interact with other medications?
What drug class is glycopyrrolate?
What pregnancy or breastfeeding source fields are listed for glycopyrrolate?
Has glycopyrrolate been recalled?
Active Recalls
Failed Impurities/Degradation Specifications
NOVADOZ PHARMACEUTICALS LLC
Related Medications in Long-Acting Muscarinic Antagonist (LAMA)
Other drugs grouped near glycopyrrolate - same-class peers and common alternatives.
aclidinium
Tudorza Pressair
Compare with glycopyrrolate →
albuterol
Ventolin, ProAir
Albuterol is a drug that helps you breathe easier.
Compare with glycopyrrolate →
albuterol/ipratropium
Combivent Respimat, DuoNeb
Combivent Respimat is a combination medicine that helps open your airways.
Compare with glycopyrrolate →
beclomethasone
Qvar
Qvar Redihaler is an inhaled medicine that helps control asthma symptoms.
Compare with glycopyrrolate →
benralizumab
Fasenra
Fasenra is a medicine that can help treat severe asthma and EGPA.
Compare with glycopyrrolate →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for glycopyrrolate: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 5,225.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 12.06%.
- galantamine Δ 0.05 pts · 1,577 reports · Acetylcholinesterase Inhibitor 12.11%death share
- colchicine Δ 0.07 pts · 28,502 reports · Anti-Gout Agent 11.99%death share
- carvedilol Δ 0.11 pts · 130,791 reports · Beta-Blocker (Alpha/Beta) 12.17%death share
- cefuroxime Δ 0.12 pts · 11,087 reports · Second-Generation Cephalosporin 11.94%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on glycopyrrolate
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for glycopyrrolate
The FDA label for glycopyrrolate (sold under brand names such as Seebri, Lonhala) classifies it as a prescription-only medication in the Long-Acting Muscarinic Antagonist (LAMA) class. This medicine can help reduce saliva and other secretions before surgery. Official labeling lists 15 commonly reported side effects, including Dry mouth, Trouble urinating, Blurred vision.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 5,225 voluntary reports. The database also lists 2 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated minor severity. NADAC pricing from CMS shows a generic unit cost of $1.40.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history (currently 1 recall record on file), and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: November 18, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages